Email Updates

You are here

Home»Media

AVAC in the News

  • ‘It’s Always Fear-Based’: Why Sexual Health Projects Should Switch the Focus To Pleasure

    In the village in Kenya where Swiry Nyar Kano (not her real name) grew up, sex and diversity weren’t talked about much. The topics didn’t come up in conversation with her parents, and at school she was taught about human anatomy and “sexual immorality”, and told that homosexuality was a sin. “I grew up in society where sex was about having babies and that was about it,” says the social media influencer. “Sexuality was never mentioned. Nobody ever talked about it so I started seeking answers for myself.”

    November 22, 2022
    General
    The Guardian

  • A New Shot Guards Against HIV, but Access for Africans Is Uncertain

    For seven years, a daily pill has been available in South Africa to protect people from getting HIV. But when Victoria Makhandule, a community health worker, counsels the young women in her township about the medication, they tell her it doesn’t work for them. These young women are among the most vulnerable in the world to HIV, the virus that causes AIDS, but they say the daily pills, known as PrEP, bring their own challenges. The women may spend an unexpected night away from home and miss a dose, or forget for a day or two.

    September 27, 2022
    PrEP
    The New York Times

  • Safety Data Needed for Concurrent Use of ARV-Based PrEP

    Women at risk of acquiring HIV have increasing antiretroviral-based options for HIV prevention, with long-acting injectable cabotegravir and oral tenofovir-based tablets approved by the US Food and Drug Administration for use as pre-exposure prophylaxis (PrEP). The dapivirine vaginal ring received a favourable scientific opinion by the European Medicines Agency in 2020, was recommended by WHO in 2021, and has been approved for PrEP use in several African countries.

    September 27, 2022
    PrEP
    The Lancet HIV

  • Government Can’t Mandate Coverage for Drugs That Prevent HIV Infections, Texas Federal Judge Rules

    A federal judge in Texas has ruled that a provision of the Affordable Care Act that mandates free coverage of certain drugs that prevent HIV infections violates the religious beliefs of a Christian-owned company. The ruling by U.S. District Judge Reed O’Connor came in response to a lawsuit filed by Jonathan Mitchell, a former Texas solicitor general and a conservative activist, on behalf of Braidwood Management Inc. and other self-described Christian employers and employees.

    September 7, 2022
    PrEP
    NBC News

  • The HIV Prevention Drug That Could Save Millions of People – If They Can Afford It

    Someone was blowing a whistle. A crowd with placards surged into the conference room, chanting “PrEP costs pennies, ViiV’s greed kills”. Not an obvious slogan, but everyone in the room knew what it meant. The protesters took over the stage, denouncing “pharma’s greed” at the microphone. On the platform, those whose session had been interrupted smiled, even applauded. “Thank you for your advocacy. Please allow the session to continue,” read prepared slides on the overhead screens.

    August 3, 2022
    PrEP
    The Guardian

  • The HIV Prevention Drug That Could Save Millions of People – If They Can Afford It

    Someone was blowing a whistle. A crowd with placards surged into the conference room, chanting “PrEP costs pennies, ViiV’s greed kills”. Not an obvious slogan, but everyone in the room knew what it meant. The protesters took over the stage, denouncing “pharma’s greed” at the microphone. On the platform, those whose session had been interrupted smiled, even applauded. “Thank you for your advocacy. Please allow the session to continue,” read prepared slides on the overhead screens.

    August 3, 2022
    PrEP
    The Guardian

  • Just Six Injections a Year Can Prevent HIV: Here’s What It Will Take for the World To Afford Them

    An injection every two months of the antiretroviral cabotegravir is the most effective way to prevent HIV that the world has ever seen. Making it affordable will depend, in part, on how many generic manufacturers will invest in producing it — and for that, the world must show the promise of markets: millions of otherwise healthy people who will line up at a pharmacy or clinic for a quick injection every two months. The question is: how do you create a market for a product that most of the world has not yet seen?

    August 2, 2022
    PrEP
    aidsmap

  • GSK, Still Early in US Launch, Licenses Long-Acting HIV PrEP Drug Apretude To Patent Pool for Poorer Nations

    Antivirals have historically made up the bulk of licenses that allow generic companies to copy innovative drugs for poorer countries. Now, GSK’s ViiV Healthcare is adding the world’s first long-acting HIV prevention med to a patent-sharing program merely seven months into an FDA approval. GSK has signed a licensing deal with the United Nations-backed Medicines Patent Pool (MPP) for its long-acting HIV PrEP drug Apretude, or cabotegravir, the two parties unveiled during the 24th International AIDS Conference.

    July 28, 2022
    PrEP
    Fierce Pharma

  • Stop Squandering Opportunities To End AIDS: Be Responsive to the Needs of HIV Prevention Users

    en years ago this month, the Food and Drug Administration approved a daily pill that was up to 99% effective in preventing infection with HIV, the virus that causes AIDS. Expectations were high that this approach, known as oral pre-exposure prophylaxis (PrEP), could change the course of the AIDS pandemic. It hasn’t. The use of oral PrEP today is stubbornly low, while HIV rates remain tenaciously high.

    July 19, 2022
    PrEP
    Stat

  • A Decade After Approval, PrEP Hasn’t Reached Its Full Potential

    On July 16, 2012, the Food and Drug Administration (FDA) approved Truvada for pre-exposure prophylaxis—better known as PrEP—to prevent HIV acquisition. But although uptake has improved over the past decade, PrEP still isn’t reaching everyone at risk for HIV.

    July 16, 2022
    PrEP
    POZ Magazine

Pages